ID   PTN13_HUMAN             Reviewed;        2485 AA.
AC   Q12923; B2RTR0; Q15159; Q15263; Q15264; Q15265; Q15674; Q16826;
AC   Q8IWH7; Q9NYN9; Q9UDA8;
DT   01-DEC-2000, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-2000, sequence version 2.
DT   10-MAY-2017, entry version 189.
DE   RecName: Full=Tyrosine-protein phosphatase non-receptor type 13;
DE            EC=3.1.3.48;
DE   AltName: Full=Fas-associated protein-tyrosine phosphatase 1;
DE            Short=FAP-1;
DE   AltName: Full=PTP-BAS;
DE   AltName: Full=Protein-tyrosine phosphatase 1E;
DE            Short=PTP-E1;
DE            Short=hPTPE1;
DE   AltName: Full=Protein-tyrosine phosphatase PTPL1;
GN   Name=PTPN13; Synonyms=PNP1, PTP1E, PTPL1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4).
RC   TISSUE=Mammary carcinoma;
RX   PubMed=8071359;
RA   Banville D., Ahmad S., Stocco R., Shen S.-H.;
RT   "A novel protein-tyrosine phosphatase with homology to both the
RT   cytoskeletal proteins of the band 4.1 family and junction-associated
RT   guanylate kinases.";
RL   J. Biol. Chem. 269:22320-22327(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2 AND 3), AND ALTERNATIVE
RP   SPLICING.
RC   TISSUE=Leukemia;
RX   PubMed=8287977; DOI=10.1016/0014-5793(94)80273-4;
RA   Maekawa K., Imagawa N., Nagamatsu M., Harada S.;
RT   "Molecular cloning of a novel protein-tyrosine phosphatase containing
RT   a membrane-binding domain and GLGF repeats.";
RL   FEBS Lett. 337:200-206(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RC   TISSUE=Fibroblast;
RX   PubMed=7929060;
RA   Saras J., Claesson-Welsh L., Heldin C.-H., Gonez L.J.;
RT   "Cloning and characterization of PTPL1, a protein tyrosine phosphatase
RT   with similarities to cytoskeletal-associated proteins.";
RL   J. Biol. Chem. 269:24082-24089(1994).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3), AND NUCLEOTIDE
RP   SEQUENCE [LARGE SCALE MRNA] OF 1323-1922 (ISOFORM 1).
RC   TISSUE=Brain, and Eye;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1216-2485 (ISOFORMS 1/2/3).
RC   TISSUE=Pancreas;
RA   Wang H.-Y.;
RL   Submitted (JUN-1994) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1279-1883 (ISOFORM 4).
RC   TISSUE=Brain;
RX   PubMed=7536343; DOI=10.1126/science.7536343;
RA   Sato T., Irie S., Kitada S., Reed J.C.;
RT   "FAP-1: a protein tyrosine phosphatase that associates with Fas.";
RL   Science 268:411-415(1995).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1323-1821 (ISOFORMS 1/2/3), AND
RP   INTERACTION WITH NGFR.
RX   PubMed=10544233; DOI=10.1016/S0014-5793(99)01324-1;
RA   Irie S., Hachiya T., Rabizadeh S., Maruyama W., Mukai J., Li Y.,
RA   Reed J.C., Bredesen D.E., Sato T.A.;
RT   "Functional interaction of Fas-associated phosphatase-1 (FAP-1) with
RT   p75(NTR) and their effect on NF-kappaB activation.";
RL   FEBS Lett. 460:191-198(1999).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 2298-2414.
RC   TISSUE=Leukemia;
RX   PubMed=8483328;
RA   Honda H., Shibuya M., Chiba S., Yazaki Y., Hirai H.;
RT   "Identification of novel protein-tyrosine phosphatases in a human
RT   leukemia cell line, F-36P.";
RL   Leukemia 7:742-746(1993).
RN   [9]
RP   INTERACTION WITH ARHGAP29.
RX   PubMed=9305890; DOI=10.1074/jbc.272.39.24333;
RA   Saras J., Franzen P., Aspenstroem P., Hellman U., Gonez L.J.,
RA   Heldin C.-H.;
RT   "A novel GTPase-activating protein for Rho interacts with a PDZ domain
RT   of the protein-tyrosine phosphatase PTPL1.";
RL   J. Biol. Chem. 272:24333-24338(1997).
RN   [10]
RP   INTERACTION WITH TRIP6.
RX   PubMed=10400701; DOI=10.1074/jbc.274.29.20679;
RA   Murthy K.K., Clark K., Fortin Y., Shen S.-H., Banville D.;
RT   "ZRP-1, a zyxin-related protein, interacts with the second PDZ domain
RT   of the cytosolic protein tyrosine phosphatase hPTP1E.";
RL   J. Biol. Chem. 274:20679-20687(1999).
RN   [11]
RP   INTERACTION WITH PKN2, AND SUBCELLULAR LOCATION.
RX   PubMed=11356191; DOI=10.1016/S0014-5793(01)02401-2;
RA   Gross C., Heumann R., Erdmann K.S.;
RT   "The protein kinase C-related kinase PRK2 interacts with the protein
RT   tyrosine phosphatase PTP-BL via a novel PDZ domain binding motif.";
RL   FEBS Lett. 496:101-104(2001).
RN   [12]
RP   INTERACTION WITH PLEKHA1 AND PLEKHA2.
RX   PubMed=14516276; DOI=10.1042/BJ20031154;
RA   Kimber W.A., Deak M., Prescott A.R., Alessi D.R.;
RT   "Interaction of the protein tyrosine phosphatase PTPL1 with the
RT   PtdIns(3,4)P2-binding adaptor protein TAPP1.";
RL   Biochem. J. 376:525-535(2003).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1029 AND SER-1033, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-240; SER-890; SER-908
RP   AND SER-1085, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [17]
RP   FUNCTION, AND INTERACTION WITH FBXL2 AND PIK3R2.
RX   PubMed=23604317; DOI=10.1038/ncb2731;
RA   Kuchay S., Duan S., Schenkein E., Peschiaroli A., Saraf A.,
RA   Florens L., Washburn M.P., Pagano M.;
RT   "FBXL2- and PTPL1-mediated degradation of p110-free p85beta regulatory
RT   subunit controls the PI(3)K signalling cascade.";
RL   Nat. Cell Biol. 15:472-480(2013).
RN   [18]
RP   INTERACTION WITH SDCCAG3.
RX   PubMed=23108400; DOI=10.1038/onc.2012.485;
RA   Hagemann N., Ackermann N., Christmann J., Brier S., Yu F.,
RA   Erdmann K.S.;
RT   "The serologically defined colon cancer antigen-3 interacts with the
RT   protein tyrosine phosphatase PTPN13 and is involved in the regulation
RT   of cytokinesis.";
RL   Oncogene 32:4602-4613(2013).
RN   [19]
RP   STRUCTURE BY NMR OF 1361-1456 UNCOMPLEXED AND IN COMPLEX WITH THE
RP   C-TERMINUS OF TNFRSF6.
RX   PubMed=10704206; DOI=10.1021/bi991913c;
RA   Kozlov G., Gehring K., Ekiel I.;
RT   "Solution structure of the PDZ2 domain from human phosphatase hPTP1E
RT   and its interactions with C-terminal peptides from the Fas receptor.";
RL   Biochemistry 39:2572-2580(2000).
RN   [20]
RP   STRUCTURE BY NMR OF 1361-1456 IN COMPLEX WITH THE C-TERMINUS OF THE
RP   GUANINE NUCLEOTIDE EXCHANGE FACTOR RA-GEF-2.
RX   PubMed=12095257; DOI=10.1016/S0022-2836(02)00544-2;
RA   Kozlov G., Banville D., Gehring K., Ekiel I.;
RT   "Solution structure of the PDZ2 domain from cytosolic human
RT   phosphatase hPTP1E complexed with a peptide reveals contribution of
RT   the beta2-beta3 loop to PDZ domain-ligand interactions.";
RL   J. Mol. Biol. 320:813-820(2002).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) OF 2163-2477, FUNCTION,
RP   MUTAGENESIS OF ASP-2154; ARG-2205; GLN-2221; MET-2307; CYS-2408;
RP   ARG-2444; HIS-2448; GLY-2449 AND GLU-2474, AND CHARACTERIZATION OF
RP   VARIANT VAL-2458.
RX   PubMed=15611135; DOI=10.1074/jbc.M412211200;
RA   Villa F., Deak M., Bloomberg G.B., Alessi D.R., van Aalten D.M.;
RT   "Crystal structure of the PTPL1/FAP-1 human tyrosine phosphatase
RT   mutated in colorectal cancer: evidence for a second phosphotyrosine
RT   substrate recognition pocket.";
RL   J. Biol. Chem. 280:8180-8187(2005).
RN   [22]
RP   VARIANTS PRO-1419 AND MET-1522.
RX   PubMed=12436199; DOI=10.1007/s100380200094;
RA   Yoshida S., Harada H., Nagai H., Fukino K., Teramoto A., Emi M.;
RT   "Head-to-head juxtaposition of Fas-associated phosphatase-1 (FAP-1)
RT   and c-Jun NH2-terminal kinase 3 (JNK3) genes: genomic structure and
RT   seven polymorphisms of the FAP-1 gene.";
RL   J. Hum. Genet. 47:614-619(2002).
CC   -!- FUNCTION: Tyrosine phosphatase which regulates negatively FAS-
CC       induced apoptosis and NGFR-mediated pro-apoptotic signaling
CC       (PubMed:15611135). May regulate phosphoinositide 3-kinase (PI3K)
CC       signaling through dephosphorylation of PIK3R2 (PubMed:23604317).
CC       {ECO:0000269|PubMed:15611135, ECO:0000269|PubMed:23604317}.
CC   -!- CATALYTIC ACTIVITY: Protein tyrosine phosphate + H(2)O = protein
CC       tyrosine + phosphate.
CC   -!- SUBUNIT: Interacts with TRIP6 and TNFRSF6 (Fas receptor) through
CC       its second PDZ domain. Interacts with the C-terminal SVP motif of
CC       NGFR through its third PDZ domain. Interacts with the LIM domain
CC       of PDLIM4 through its second and fourth PDZ domains. Binds PLEKHA1
CC       and PLEKHA2 through its first PDZ domain. Interacts with BRD7.
CC       Interacts with ARHGAP29. Interacts (via PDZ 3 domain) with PKN2
CC       (via C-terminus). Interacts with PIK3R2; dephosphorylates PIK3R2
CC       (PubMed:23604317). Interacts with FBXL2 (PubMed:23604317).
CC       Interacts with SDCCAG3 (PubMed:23108400).
CC       {ECO:0000269|PubMed:10400701, ECO:0000269|PubMed:10544233,
CC       ECO:0000269|PubMed:10704206, ECO:0000269|PubMed:11356191,
CC       ECO:0000269|PubMed:12095257, ECO:0000269|PubMed:14516276,
CC       ECO:0000269|PubMed:23108400, ECO:0000269|PubMed:23604317,
CC       ECO:0000269|PubMed:9305890}.
CC   -!- INTERACTION:
CC       P25445:FAS; NbExp=3; IntAct=EBI-355227, EBI-494743;
CC       Q9BUL8:PDCD10; NbExp=3; IntAct=EBI-355227, EBI-740195;
CC       Q8TEU7:RAPGEF6; NbExp=4; IntAct=EBI-355227, EBI-2693017;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton {ECO:0000250}.
CC       Nucleus {ECO:0000269|PubMed:11356191}. Cell projection,
CC       lamellipodium {ECO:0000269|PubMed:11356191}. Note=Colocalizes with
CC       PKN2 in lamellipodia-like structure, regions of large actin
CC       turnover.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=Q12923-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q12923-2; Sequence=VSP_000496;
CC       Name=3;
CC         IsoId=Q12923-3; Sequence=VSP_000497;
CC       Name=4;
CC         IsoId=Q12923-4; Sequence=VSP_007921;
CC         Note=May be due to a competing donor splice site.;
CC   -!- TISSUE SPECIFICITY: Present in most tissues with the exception of
CC       the liver and skeletal muscle. Most abundant in lung, kidney and
CC       fetal brain.
CC   -!- SIMILARITY: Belongs to the protein-tyrosine phosphatase family.
CC       Non-receptor class subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH39610.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/PTPN13ID41912ch4q21.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U12128; AAB60339.1; -; mRNA.
DR   EMBL; D21209; BAA04750.1; -; mRNA.
DR   EMBL; D21210; BAA04751.1; -; mRNA.
DR   EMBL; D21211; BAA04752.1; -; mRNA.
DR   EMBL; X80289; CAA56563.1; -; mRNA.
DR   EMBL; BC039610; AAH39610.1; ALT_SEQ; mRNA.
DR   EMBL; BC140777; AAI40778.1; -; mRNA.
DR   EMBL; X79676; CAA56124.1; -; mRNA.
DR   EMBL; L34583; AAC41755.1; -; mRNA.
DR   EMBL; AF233323; AAF63474.1; -; mRNA.
DR   CCDS; CCDS47093.1; -. [Q12923-4]
DR   CCDS; CCDS47094.1; -. [Q12923-1]
DR   CCDS; CCDS47095.1; -. [Q12923-3]
DR   CCDS; CCDS47096.1; -. [Q12923-2]
DR   PIR; A54971; A54971.
DR   PIR; I67629; I67629.
DR   PIR; I67630; I67630.
DR   RefSeq; NP_006255.1; NM_006264.2. [Q12923-3]
DR   RefSeq; NP_542414.1; NM_080683.2. [Q12923-1]
DR   RefSeq; NP_542415.1; NM_080684.2. [Q12923-2]
DR   RefSeq; NP_542416.1; NM_080685.2. [Q12923-4]
DR   UniGene; Hs.436142; -.
DR   PDB; 1D5G; NMR; -; A=1361-1456.
DR   PDB; 1Q7X; NMR; -; A=1358-1459.
DR   PDB; 1WCH; X-ray; 1.85 A; A=2163-2477.
DR   PDB; 2M0Z; NMR; -; A=1361-1456.
DR   PDB; 2M10; NMR; -; A=1361-1456.
DR   PDB; 3LNX; X-ray; 1.64 A; A/B/C/D/E/F=1361-1456.
DR   PDB; 3LNY; X-ray; 1.30 A; A=1361-1456.
DR   PDB; 3PDZ; NMR; -; A=1361-1456.
DR   PDB; 5GLJ; X-ray; 1.60 A; A/B/C/D=1086-1178.
DR   PDBsum; 1D5G; -.
DR   PDBsum; 1Q7X; -.
DR   PDBsum; 1WCH; -.
DR   PDBsum; 2M0Z; -.
DR   PDBsum; 2M10; -.
DR   PDBsum; 3LNX; -.
DR   PDBsum; 3LNY; -.
DR   PDBsum; 3PDZ; -.
DR   PDBsum; 5GLJ; -.
DR   ProteinModelPortal; Q12923; -.
DR   SMR; Q12923; -.
DR   BioGrid; 111747; 22.
DR   DIP; DIP-40449N; -.
DR   IntAct; Q12923; 20.
DR   MINT; MINT-109571; -.
DR   STRING; 9606.ENSP00000394794; -.
DR   BindingDB; Q12923; -.
DR   ChEMBL; CHEMBL2976; -.
DR   DEPOD; Q12923; -.
DR   iPTMnet; Q12923; -.
DR   PhosphoSitePlus; Q12923; -.
DR   BioMuta; PTPN13; -.
DR   DMDM; 12643716; -.
DR   EPD; Q12923; -.
DR   MaxQB; Q12923; -.
DR   PaxDb; Q12923; -.
DR   PeptideAtlas; Q12923; -.
DR   PRIDE; Q12923; -.
DR   DNASU; 5783; -.
DR   Ensembl; ENST00000316707; ENSP00000322675; ENSG00000163629. [Q12923-2]
DR   Ensembl; ENST00000411767; ENSP00000407249; ENSG00000163629. [Q12923-1]
DR   Ensembl; ENST00000427191; ENSP00000408368; ENSG00000163629. [Q12923-3]
DR   Ensembl; ENST00000436978; ENSP00000394794; ENSG00000163629. [Q12923-4]
DR   Ensembl; ENST00000511467; ENSP00000426626; ENSG00000163629. [Q12923-4]
DR   GeneID; 5783; -.
DR   KEGG; hsa:5783; -.
DR   UCSC; uc003hpy.4; human. [Q12923-1]
DR   CTD; 5783; -.
DR   DisGeNET; 5783; -.
DR   GeneCards; PTPN13; -.
DR   HGNC; HGNC:9646; PTPN13.
DR   HPA; CAB002213; -.
DR   HPA; HPA065290; -.
DR   MIM; 600267; gene.
DR   neXtProt; NX_Q12923; -.
DR   OpenTargets; ENSG00000163629; -.
DR   PharmGKB; PA33988; -.
DR   eggNOG; KOG0792; Eukaryota.
DR   eggNOG; COG5599; LUCA.
DR   GeneTree; ENSGT00870000136430; -.
DR   HOVERGEN; HBG053756; -.
DR   InParanoid; Q12923; -.
DR   KO; K02374; -.
DR   OMA; GCYVHDV; -.
DR   OrthoDB; EOG091G0BZR; -.
DR   PhylomeDB; Q12923; -.
DR   TreeFam; TF315388; -.
DR   BRENDA; 3.1.3.48; 2681.
DR   Reactome; R-HSA-1660499; Synthesis of PIPs at the plasma membrane.
DR   SIGNOR; Q12923; -.
DR   ChiTaRS; PTPN13; human.
DR   EvolutionaryTrace; Q12923; -.
DR   GeneWiki; PTPN13; -.
DR   GenomeRNAi; 5783; -.
DR   PRO; PR:Q12923; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   Bgee; ENSG00000163629; -.
DR   ExpressionAtlas; Q12923; baseline and differential.
DR   Genevisible; Q12923; HS.
DR   GO; GO:0044297; C:cell body; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005856; C:cytoskeleton; IEA:UniProtKB-SubCell.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0030027; C:lamellipodium; IDA:UniProtKB.
DR   GO; GO:0043005; C:neuron projection; IEA:Ensembl.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0036312; F:phosphatidylinositol 3-kinase regulatory subunit binding; IPI:UniProtKB.
DR   GO; GO:0004725; F:protein tyrosine phosphatase activity; IDA:UniProtKB.
DR   GO; GO:0035335; P:peptidyl-tyrosine dephosphorylation; IMP:UniProtKB.
DR   GO; GO:0006661; P:phosphatidylinositol biosynthetic process; TAS:Reactome.
DR   GO; GO:0006470; P:protein dephosphorylation; IDA:UniProtKB.
DR   GO; GO:0014066; P:regulation of phosphatidylinositol 3-kinase signaling; IDA:UniProtKB.
DR   Gene3D; 1.20.80.10; -; 1.
DR   Gene3D; 2.30.29.30; -; 1.
DR   Gene3D; 3.90.190.10; -; 1.
DR   InterPro; IPR019749; Band_41_domain.
DR   InterPro; IPR014352; FERM/acyl-CoA-bd_prot_3-hlx.
DR   InterPro; IPR019748; FERM_central.
DR   InterPro; IPR000299; FERM_domain.
DR   InterPro; IPR018979; FERM_N.
DR   InterPro; IPR018980; FERM_PH-like_C.
DR   InterPro; IPR011019; KIND_dom.
DR   InterPro; IPR001478; PDZ.
DR   InterPro; IPR011993; PH_dom-like.
DR   InterPro; IPR029021; Prot-tyrosine_phosphatase-like.
DR   InterPro; IPR000242; PTPase_domain.
DR   InterPro; IPR012153; PTPN13.
DR   InterPro; IPR003595; Tyr_Pase_cat.
DR   InterPro; IPR000387; TYR_PHOSPHATASE_dom.
DR   InterPro; IPR029071; Ubiquitin-rel_dom.
DR   PANTHER; PTHR19134:SF358; PTHR19134:SF358; 1.
DR   Pfam; PF09380; FERM_C; 1.
DR   Pfam; PF00373; FERM_M; 1.
DR   Pfam; PF09379; FERM_N; 1.
DR   Pfam; PF00595; PDZ; 5.
DR   Pfam; PF00102; Y_phosphatase; 1.
DR   PIRSF; PIRSF000933; Tyr-Ptase_nr13; 1.
DR   PRINTS; PR00935; BAND41.
DR   PRINTS; PR00700; PRTYPHPHTASE.
DR   SMART; SM00295; B41; 1.
DR   SMART; SM01196; FERM_C; 1.
DR   SMART; SM00750; KIND; 1.
DR   SMART; SM00228; PDZ; 5.
DR   SMART; SM00194; PTPc; 1.
DR   SMART; SM00404; PTPc_motif; 1.
DR   SUPFAM; SSF47031; SSF47031; 1.
DR   SUPFAM; SSF50156; SSF50156; 5.
DR   SUPFAM; SSF50729; SSF50729; 1.
DR   SUPFAM; SSF52799; SSF52799; 1.
DR   SUPFAM; SSF54236; SSF54236; 1.
DR   PROSITE; PS50057; FERM_3; 1.
DR   PROSITE; PS51377; KIND; 1.
DR   PROSITE; PS50106; PDZ; 5.
DR   PROSITE; PS50056; TYR_PHOSPHATASE_2; 1.
DR   PROSITE; PS50055; TYR_PHOSPHATASE_PTP; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell projection; Coiled coil;
KW   Complete proteome; Cytoplasm; Cytoskeleton; Hydrolase; Nucleus;
KW   Phosphoprotein; Polymorphism; Protein phosphatase; Reference proteome;
KW   Repeat.
FT   CHAIN         1   2485       Tyrosine-protein phosphatase non-receptor
FT                                type 13.
FT                                /FTId=PRO_0000219435.
FT   DOMAIN        3    190       KIND. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00709}.
FT   DOMAIN      572    872       FERM. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00084}.
FT   DOMAIN     1093   1178       PDZ 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00143}.
FT   DOMAIN     1368   1452       PDZ 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00143}.
FT   DOMAIN     1501   1588       PDZ 3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00143}.
FT   DOMAIN     1788   1868       PDZ 4. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00143}.
FT   DOMAIN     1882   1965       PDZ 5. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00143}.
FT   DOMAIN     2213   2467       Tyrosine-protein phosphatase.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00160}.
FT   REGION     2408   2414       Substrate.
FT   REGION     2408   2414       Substrate binding. {ECO:0000250}.
FT   COILED      469    504       {ECO:0000255}.
FT   COMPBIAS     56     59       Poly-Leu.
FT   COMPBIAS   1742   1749       Poly-Ser.
FT   ACT_SITE   2408   2408       Phosphocysteine intermediate.
FT                                {ECO:0000305}.
FT   BINDING    2378   2378       Substrate.
FT   BINDING    2452   2452       Substrate. {ECO:0000250}.
FT   MOD_RES     240    240       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     301    301       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q64512}.
FT   MOD_RES     302    302       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q64512}.
FT   MOD_RES     890    890       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     897    897       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q64512}.
FT   MOD_RES     908    908       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     911    911       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q64512}.
FT   MOD_RES     914    914       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q64512}.
FT   MOD_RES    1029   1029       Phosphoserine.
FT                                {ECO:0000244|PubMed:21406692}.
FT   MOD_RES    1033   1033       Phosphoserine.
FT                                {ECO:0000244|PubMed:21406692}.
FT   MOD_RES    1085   1085       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   VAR_SEQ     884   1074       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:8287977}.
FT                                /FTId=VSP_000496.
FT   VAR_SEQ    1056   1074       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:7929060,
FT                                ECO:0000303|PubMed:8287977}.
FT                                /FTId=VSP_000497.
FT   VAR_SEQ    1383   1383       T -> TVLFDK (in isoform 4).
FT                                {ECO:0000303|PubMed:7536343,
FT                                ECO:0000303|PubMed:8071359}.
FT                                /FTId=VSP_007921.
FT   VARIANT    1356   1356       F -> L (in dbSNP:rs10033029).
FT                                /FTId=VAR_048359.
FT   VARIANT    1419   1419       L -> P (in dbSNP:rs749353184).
FT                                {ECO:0000269|PubMed:12436199}.
FT                                /FTId=VAR_016200.
FT   VARIANT    1522   1522       I -> M (in dbSNP:rs2230600).
FT                                {ECO:0000269|PubMed:12436199}.
FT                                /FTId=VAR_016201.
FT   VARIANT    1625   1625       E -> K (in dbSNP:rs12500797).
FT                                /FTId=VAR_024373.
FT   VARIANT    1744   1744       S -> P (in dbSNP:rs17012064).
FT                                /FTId=VAR_048360.
FT   VARIANT    2081   2081       Y -> D (in dbSNP:rs989902).
FT                                /FTId=VAR_024374.
FT   VARIANT    2458   2458       I -> V (no effect on substrate affinity;
FT                                dbSNP:rs34226837).
FT                                {ECO:0000269|PubMed:15611135}.
FT                                /FTId=VAR_048361.
FT   MUTAGEN    2154   2154       D->H: No effect on substrate affinity.
FT                                {ECO:0000269|PubMed:15611135}.
FT   MUTAGEN    2205   2205       R->W: No effect on substrate affinity.
FT                                {ECO:0000269|PubMed:15611135}.
FT   MUTAGEN    2221   2221       Q->M: Reduces substrate affinity 2 fold.
FT                                {ECO:0000269|PubMed:15611135}.
FT   MUTAGEN    2307   2307       M->T: Reduces substrate affinity 7 fold.
FT                                {ECO:0000269|PubMed:15611135}.
FT   MUTAGEN    2408   2408       C->S: Loss of catalytic activity.
FT                                {ECO:0000269|PubMed:15611135}.
FT   MUTAGEN    2444   2444       R->E: Loss of catalytic activity.
FT                                {ECO:0000269|PubMed:15611135}.
FT   MUTAGEN    2444   2444       R->K: Reduces substrate affinity 7 fold.
FT                                {ECO:0000269|PubMed:15611135}.
FT   MUTAGEN    2444   2444       R->Q: Strongly decreases catalytic
FT                                activity. {ECO:0000269|PubMed:15611135}.
FT   MUTAGEN    2448   2448       H->A: Reduces substrate affinity 2 fold.
FT                                {ECO:0000269|PubMed:15611135}.
FT   MUTAGEN    2449   2449       G->V: Loss of catalytic activity.
FT                                {ECO:0000269|PubMed:15611135}.
FT   MUTAGEN    2474   2474       E->D: No effect on substrate affinity.
FT                                {ECO:0000269|PubMed:15611135}.
FT   CONFLICT   1134   1135       LD -> FH (in Ref. 3; CAA56563).
FT                                {ECO:0000305}.
FT   CONFLICT   1216   1229       KDHHWSRGTLRHIS -> DLSRSHCHVYLAHL (in Ref.
FT                                5). {ECO:0000305}.
FT   CONFLICT   1238   1239       GL -> A (in Ref. 5; CAA56124).
FT                                {ECO:0000305}.
FT   CONFLICT   1357   1357       S -> P (in Ref. 5; CAA56124).
FT                                {ECO:0000305}.
FT   CONFLICT   1362   1363       KP -> RS (in Ref. 5; CAA56124).
FT                                {ECO:0000305}.
FT   CONFLICT   1538   1538       P -> A (in Ref. 3; CAA56563).
FT                                {ECO:0000305}.
FT   CONFLICT   1649   1649       R -> K (in Ref. 5; CAA56124).
FT                                {ECO:0000305}.
FT   CONFLICT   1698   1714       KSQEDTICTMFYYPQKI -> RVKKIPFVPCFTILRKR
FT                                (in Ref. 5; CAA56124). {ECO:0000305}.
FT   CONFLICT   1797   1797       G -> A (in Ref. 3; CAA56563).
FT                                {ECO:0000305}.
FT   CONFLICT   1856   1857       AA -> G (in Ref. 5; CAA56124).
FT                                {ECO:0000305}.
FT   CONFLICT   2069   2069       A -> S (in Ref. 5; CAA56124).
FT                                {ECO:0000305}.
FT   CONFLICT   2206   2210       GLLDQ -> VARS (in Ref. 5; CAA56124).
FT                                {ECO:0000305}.
FT   STRAND     1090   1097       {ECO:0000244|PDB:5GLJ}.
FT   TURN       1100   1102       {ECO:0000244|PDB:5GLJ}.
FT   STRAND     1105   1109       {ECO:0000244|PDB:5GLJ}.
FT   STRAND     1122   1126       {ECO:0000244|PDB:5GLJ}.
FT   HELIX      1131   1135       {ECO:0000244|PDB:5GLJ}.
FT   STRAND     1143   1147       {ECO:0000244|PDB:5GLJ}.
FT   HELIX      1157   1166       {ECO:0000244|PDB:5GLJ}.
FT   STRAND     1169   1177       {ECO:0000244|PDB:5GLJ}.
FT   STRAND     1366   1372       {ECO:0000244|PDB:3LNY}.
FT   STRAND     1374   1377       {ECO:0000244|PDB:1D5G}.
FT   STRAND     1379   1384       {ECO:0000244|PDB:3LNY}.
FT   STRAND     1385   1387       {ECO:0000244|PDB:2M0Z}.
FT   STRAND     1388   1390       {ECO:0000244|PDB:3LNY}.
FT   HELIX      1391   1393       {ECO:0000244|PDB:3LNY}.
FT   STRAND     1395   1400       {ECO:0000244|PDB:3LNY}.
FT   HELIX      1405   1409       {ECO:0000244|PDB:3LNY}.
FT   STRAND     1417   1421       {ECO:0000244|PDB:3LNY}.
FT   HELIX      1431   1439       {ECO:0000244|PDB:3LNY}.
FT   STRAND     1443   1450       {ECO:0000244|PDB:3LNY}.
FT   HELIX      2175   2179       {ECO:0000244|PDB:1WCH}.
FT   STRAND     2188   2190       {ECO:0000244|PDB:1WCH}.
FT   HELIX      2194   2209       {ECO:0000244|PDB:1WCH}.
FT   HELIX      2212   2220       {ECO:0000244|PDB:1WCH}.
FT   HELIX      2231   2233       {ECO:0000244|PDB:1WCH}.
FT   HELIX      2235   2238       {ECO:0000244|PDB:1WCH}.
FT   TURN       2257   2260       {ECO:0000244|PDB:1WCH}.
FT   STRAND     2264   2272       {ECO:0000244|PDB:1WCH}.
FT   STRAND     2275   2282       {ECO:0000244|PDB:1WCH}.
FT   HELIX      2287   2289       {ECO:0000244|PDB:1WCH}.
FT   HELIX      2290   2299       {ECO:0000244|PDB:1WCH}.
FT   STRAND     2304   2307       {ECO:0000244|PDB:1WCH}.
FT   STRAND     2311   2313       {ECO:0000244|PDB:1WCH}.
FT   STRAND     2331   2346       {ECO:0000244|PDB:1WCH}.
FT   STRAND     2348   2359       {ECO:0000244|PDB:1WCH}.
FT   TURN       2360   2363       {ECO:0000244|PDB:1WCH}.
FT   STRAND     2364   2373       {ECO:0000244|PDB:1WCH}.
FT   HELIX      2385   2398       {ECO:0000244|PDB:1WCH}.
FT   STRAND     2404   2407       {ECO:0000244|PDB:1WCH}.
FT   STRAND     2409   2412       {ECO:0000244|PDB:1WCH}.
FT   HELIX      2413   2429       {ECO:0000244|PDB:1WCH}.
FT   HELIX      2436   2444       {ECO:0000244|PDB:1WCH}.
FT   HELIX      2454   2475       {ECO:0000244|PDB:1WCH}.
SQ   SEQUENCE   2485 AA;  276906 MW;  8D1B31597C66962B CRC64;
     MHVSLAEALE VRGGPLQEEE IWAVLNQSAE SLQELFRKVS LADPAALGFI ISPWSLLLLP
     SGSVSFTDEN ISNQDLRAFT APEVLQNQSL TSLSDVEKIH IYSLGMTLYW GADYEVPQSQ
     PIKLGDHLNS ILLGMCEDVI YARVSVRTVL DACSAHIRNS NCAPSFSYVK HLVKLVLGNL
     SGTDQLSCNS EQKPDRSQAI RDRLRGKGLP TGRSSTSDVL DIQKPPLSHQ TFLNKGLSKS
     MGFLSIKDTQ DENYFKDILS DNSGREDSEN TFSPYQFKTS GPEKKPIPGI DVLSKKKIWA
     SSMDLLCTAD RDFSSGETAT YRRCHPEAVT VRTSTTPRKK EARYSDGSIA LDIFGPQKMD
     PIYHTRELPT SSAISSALDR IRERQKKLQV LREAMNVEEP VRRYKTYHGD VFSTSSESPS
     IISSESDFRQ VRRSEASKRF ESSSGLPGVD ETLSQGQSQR PSRQYETPFE GNLINQEIML
     KRQEEELMQL QAKMALRQSR LSLYPGDTIK ASMLDITRDP LREIALETAM TQRKLRNFFG
     PEFVKMTIEP FISLDLPRSI LTKKGKNEDN RRKVNIMLLN GQRLELTCDT KTICKDVFDM
     VVAHIGLVEH HLFALATLKD NEYFFVDPDL KLTKVAPEGW KEEPKKKTKA TVNFTLFFRI
     KFFMDDVSLI QHTLTCHQYY LQLRKDILEE RMHCDDETSL LLASLALQAE YGDYQPEVHG
     VSYFRMEHYL PARVMEKLDL SYIKEELPKL HNTYVGASEK ETELEFLKVC QRLTEYGVHF
     HRVHPEKKSQ TGILLGVCSK GVLVFEVHNG VRTLVLRFPW RETKKISFSK KKITLQNTSD
     GIKHGFQTDN SKICQYLLHL CSYQHKFQLQ MRARQSNQDA QDIERASFRS LNLQAESVRG
     FNMGRAISTG SLASSTLNKL AVRPLSVQAE ILKRLSCSEL SLYQPLQNSS KEKNDKASWE
     EKPREMSKSY HDLSQASLYP HRKNVIVNME PPPQTVAELV GKPSHQMSRS DAESLAGVTK
     LNNSKSVASL NRSPERRKHE SDSSSIEDPG QAYVLGMTMH SSGNSSSQVP LKENDVLHKR
     WSIVSSPERE ITLVNLKKDA KYGLGFQIIG GEKMGRLDLG IFISSVAPGG PADLDGCLKP
     GDRLISVNSV SLEGVSHHAA IEILQNAPED VTLVISQPKE KISKVPSTPV HLTNEMKNYM
     KKSSYMQDSA IDSSSKDHHW SRGTLRHISE NSFGPSGGLR EGSLSSQDSR TESASLSQSQ
     VNGFFASHLG DQTWQESQHG SPSPSVISKA TEKETFTDSN QSKTKKPGIS DVTDYSDRGD
     SDMDEATYSS SQDHQTPKQE SSSSVNTSNK MNFKTFSSSP PKPGDIFEVE LAKNDNSLGI
     SVTGGVNTSV RHGGIYVKAV IPQGAAESDG RIHKGDRVLA VNGVSLEGAT HKQAVETLRN
     TGQVVHLLLE KGQSPTSKEH VPVTPQCTLS DQNAQGQGPE KVKKTTQVKD YSFVTEENTF
     EVKLFKNSSG LGFSFSREDN LIPEQINASI VRVKKLFPGQ PAAESGKIDV GDVILKVNGA
     SLKGLSQQEV ISALRGTAPE VFLLLCRPPP GVLPEIDTAL LTPLQSPAQV LPNSSKDSSQ
     PSCVEQSTSS DENEMSDKSK KQCKSPSRRD SYSDSSGSGE DDLVTAPANI SNSTWSSALH
     QTLSNMVSQA QSHHEAPKSQ EDTICTMFYY PQKIPNKPEF EDSNPSPLPP DMAPGQSYQP
     QSESASSSSM DKYHIHHISE PTRQENWTPL KNDLENHLED FELEVELLIT LIKSEKGSLG
     FTVTKGNQRI GCYVHDVIQD PAKSDGRLKP GDRLIKVNDT DVTNMTHTDA VNLLRAASKT
     VRLVIGRVLE LPRIPMLPHL LPDITLTCNK EELGFSLCGG HDSLYQVVYI SDINPRSVAA
     IEGNLQLLDV IHYVNGVSTQ GMTLEEVNRA LDMSLPSLVL KATRNDLPVV PSSKRSAVSA
     PKSTKGNGSY SVGSCSQPAL TPNDSFSTVA GEEINEISYP KGKCSTYQIK GSPNLTLPKE
     SYIQEDDIYD DSQEAEVIQS LLDVVDEEAQ NLLNENNAAG YSCGPGTLKM NGKLSEERTE
     DTDCDGSPLP EYFTEATKMN GCEEYCEEKV KSESLIQKPQ EKKTDDDEIT WGNDELPIER
     TNHEDSDKDH SFLTNDELAV LPVVKVLPSG KYTGANLKSV IRVLRGLLDQ GIPSKELENL
     QELKPLDQCL IGQTKENRRK NRYKNILPYD ATRVPLGDEG GYINASFIKI PVGKEEFVYI
     ACQGPLPTTV GDFWQMIWEQ KSTVIAMMTQ EVEGEKIKCQ RYWPNILGKT TMVSNRLRLA
     LVRMQQLKGF VVRAMTLEDI QTREVRHISH LNFTAWPDHD TPSQPDDLLT FISYMRHIHR
     SGPIITHCSA GIGRSGTLIC IDVVLGLISQ DLDFDISDLV RCMRLQRHGM VQTEDQYIFC
     YQVILYVLTR LQAEEEQKQQ PQLLK
//
